ALNYLAM PHARMACEUTICALS, INC. — Net Income by Fiscal Year
18 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/2147f1c7-9b39-4c0a-adf5-27303ed6404f/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $313.7M | 2025-01-01 – 2025-12-31 | evidence 0001628280-26-007497 |
| FY 2024 | $-278.2M | 2024-01-01 – 2024-12-31 | evidence 0001178670-25-000026 |
| FY 2023 | $-440.2M | 2023-01-01 – 2023-12-31 | evidence 0001178670-24-000008 |
| FY 2022 | $-1.1B | 2022-01-01 – 2022-12-31 | evidence 0001178670-23-000005 |
| FY 2021 | $-852.8M | 2021-01-01 – 2021-12-31 | evidence 0001178670-22-000013 |
| FY 2020 | $-858.3M | 2020-01-01 – 2020-12-31 | evidence 0001178670-21-000010 |
| FY 2019 | $-886.1M | 2019-01-01 – 2019-12-31 | evidence 0001178670-20-000004 |
| FY 2018 | $-761.5M | 2018-01-01 – 2018-12-31 | evidence 0001564590-19-003022 |
| FY 2017 | $-490.9M | 2017-01-01 – 2017-12-31 | evidence 0001564590-18-002152 |
| FY 2016 | $-410.1M | 2016-01-01 – 2016-12-31 | evidence 0001564590-17-001649 |
| FY 2015 | $-290.1M | 2015-01-01 – 2015-12-31 | evidence 0001193125-16-462538 |
| FY 2014 | $-360.4M | 2014-01-01 – 2014-12-31 | evidence 0001193125-15-050223 |
| FY 2013 | $-89.2M | 2013-01-01 – 2013-12-31 | evidence 0001193125-14-060913 |
| FY 2012 | $-106.0M | 2012-01-01 – 2012-12-31 | evidence 0001193125-13-065475 |
| FY 2011 | $-57.6M | 2011-01-01 – 2011-12-31 | evidence 0001193125-12-053552 |
| FY 2010 | $-43.5M | 2010-01-01 – 2010-12-31 | evidence 0000950123-11-015737 |
| FY 2009 | $-47.6M | 2009-01-01 – 2009-12-31 | evidence 0000950123-11-015737 |
| FY 2008 | $-26.2M | 2008-01-01 – 2008-12-31 | evidence 0000950123-11-015737 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
ALNYLAM PHARMACEUTICALS, INC. — all facts · Revenue · Operating Income